Ведение пациенток с генитальным эндометриозом: новые стратегии

   Цель обзора: провести анализ современных подходов к диагностике и лечению генитального эндометриоза.

   Основные положения. Эндометриоз — это одно из самых распространенных гинекологических заболеваний, поражающее прежде всего женщин репродуктивного возраста, основные проявления которого — хроническая тазовая боль и бесплодие. Постоянная снижающая качество жизни тазовая боль приводит к тому, что пациентки находятся в состоянии длительного стресса, и у них возникают расстройства поведения. Согласно последним мировым рекомендациям, медикаментозное лечение — первая линия терапии эндометриоза, если беременность не является приоритетной задачей на данном этапе. Существует множество визуализационных методов диагностики этого заболевания, однако до сих пор продолжается поиск неинвазивных маркеров эндометриоза, позволяющих достоверно подтвердить диагноз.

   Заключение. Междисциплинарный подход и выбор адекватного лечения эндометриоза на каждом этапе жизни женщины могут ограничить ненужные хирургические вмешательства и лучше удовлетворять потребности пациенток.

1. Zondervan K.T., Becker C.M., Missmer S.A. Endometriosis. N. Engl. J. Med. 2020;382(13):1244–56. DOI: 10.1056/NEJMra1810764

2. Hill C.J., Fakhreldin M., Maclean A., Dobson L. et al. Endometriosis and fallopian tubes: theories of origin and clinical implications. J. Clin. Med. 2020;9(6):1905. DOI: 10.3390/jcm9061905

3. Parazzini F., Esposito G., Tozzi L., Noli S. et al. Epidemiology of endometriosis and its comorbidities. Eur. J. Obstet. Gynecol. Reprod. Biol. 2017;209:3–7. DOI: 10.1016/j.ejogrb.2016.04.021

4. Gambadauro P., Carli V., Hadlaczky G. Depressive symptoms among women with endometriosis : a systematic review and meta-analysis. Am. J. Obstet. Gynecol. 2019;220(3):230–41. DOI: 10.1016/j.ajog.2018.11.123

5. As-Sanie S., Black R., Giudice L.C., Gray Valbrun T. et al. Assessing research gaps and unmet needs in endometriosis. Am. J. Obstet. Gynecol. 2019;221(2):86–94. DOI: 10.1016/j.ajog.2019.02.033

6. Škegro B., Bjedov S., Mikuš M., Mustač F. et al. Endometriosis, pain and mental health. Psychiatr. Danub. 2021;33(suppl.4):632–6.

7. Casalechi M., Vieira-Lopes M., Quessada M.P., Arão T.C. et al. Endometriosis and related pelvic pain: association with stress, anxiety and depressive symptoms. Minerva Obstet Gynecol. 2021;73(3):283–9. DOI: 10.23736/S2724-606X.21.04704-3

8. Walker A.K., Kavelaars A., Heijnen C.J., Dantzer R. Neuroinflammation and comorbidity of pain and depression. Pharmacol. Rev. 2013;66(1):80–101. DOI: 10.1124/pr.113.008144

9. Harsanyi S., Kupcova I., Danisovic L., Klein M. Selected biomarkers of depression: what are the effects of cytokines and inflammation? Int. J. Mol. Sci. 2022;24(1):578. DOI: 10.3390/ijms24010578

10. Howren M.B., Lamkin D.M., Suls J. Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom. Med. 2009;71(2):171–86. DOI: 10.1097/PSY.0b013e3181907c1b

11. Nabi M.Y., Nauhria S., Reel M., Londono S. et al. Endometriosis and irritable bowel syndrome: a systematic review and meta-analyses. Front. Med. (Lausanne). 2022;9:914356. DOI: 10.3389/fmed.2022.914356

12. Schomacker M.L., Hansen K.E., Ramlau-Hansen C.H., Forman A. Is endometriosis associated with irritable bowel syndrome? A cross-sectional study. Eur. J. Obstet. Gynecol. Reprod. Biol. 2018;231:65–9. DOI: 10.1016/j.ejogrb.2018.10.023

13. Baker J.M., Al-Nakkash L., Herbst-Kralovetz M.M. Estrogen-gut microbiome axis: physiological and clinical implications. Maturitas. 2017;103:45–53. DOI: 10.1016/j.maturitas.2017.06.025

14. Rowlands I.J., Hockey R., Abbott J.A., Montgomery G.W. et al. Body mass index and the diagnosis of endometriosis: findings from a national data linkage cohort study. Obes. Res. Clin. Pract. 2022;16(3):235–41. DOI: 10.1016/j.orcp.2022.04.002

15. Vercellini P., Eskenazi B., Consonni D., Somigliana E. et al. Oral contraceptives and risk of endometriosis : a systematic review and meta-analysis. Hum. Reprod. Update. 2011;17(2):159–70. DOI: 10.1093/humupd/dmq042

16. Chapron C., Souza C., Borghese B., Lafay-Pillet M.C. et al. Oral contraceptives and endometriosis: the past use of oral contraceptives for treating severe primary dysmenorrhea is associated with endometriosis, especially deep infiltrating endometriosis. Hum. Reprod. 2011;26(8):2028–35. DOI: 10.1093/humrep/der156

17. Moura A.P.C., Ribeiro H.S.A.A., Bernardo W.M., Simões R. et al. Accuracy of transvaginal sonography versus magnetic resonance imaging in the diagnosis of rectosigmoid endometriosis : systematic review and meta-analysis [published correction appears in PLoS One. 2019;14(8):e0221499]. PLoS One. 2019;14(4):e0214842. DOI: 10.1371/journal.pone.0214842

18. Chowdary P., Stone K., Ma T., Readman E. et al. Multicentre retrospective study to assess diagnostic accuracy of ultrasound for superficial endometriosis — are we any closer? Aust. N. Z. J. Obstet. Gynaecol. 2019;59(2):279–84. DOI: 10.1111/ajo.12911

19. Guo C., Zhang C. Platelet-to-lymphocyte ratio and CA125 level as a combined biomarker for diagnosing endometriosis and predicting pelvic adhesion severity. Front. Oncol. 2022;12:896152. DOI: 10.3389/fonc.2022.896152

20. Xue Y.H., You L.T., Ting H.F., Chen Y.W. et al. Increased risk of rheumatoid arthritis among patients with endometriosis: a nationwide population-based cohort study. Rheumatology (Oxford). 2021;60(7):3326–33. DOI: 10.1093/rheumatology/keaa784

21. Kusunoki M., Fujiwara Y., Komohara Y., Imamura Y. et al. Hemoglobin-induced continuous activation of macrophages in endometriotic cysts: a potential mechanism of endometriosis development and carcinogenesis. Med. Mol. Morphol. 2021;54(2):122–32. DOI: 10.1007/s00795-020-00272-4

22. Chapron C., Marcellin L., Borghese B., Santulli P. Rethinking mechanisms, diagnosis and management of endometriosis. Nat. Rev. Endocrinol. 2019;15(11):666–82. DOI: 10.1038/s41574-019-0245-z

23. Kitajima M., Khan K.N., Harada A., Taniguchi K. et al. Association between ovarian endometrioma and ovarian reserve. Front. Biosci. (Elite Ed). 2018;10(1):92–102. DOI: 10.2741/e810

24. Muzii L., Galati G., Di Tucci C., Di Feliciantonio M. et al. Medical treatment of ovarian endometriomas: a prospective evaluation of the effect of dienogest on ovarian reserve, cyst diameter, and associated pain. Gynecol. Endocrinol. 2020;36(1):81–3. DOI: 10.1080/09513590.2019.1640199

25. Králíčková M., Laganà A.S., Ghezzi F., Vetvicka V. Endometriosis and risk of ovarian cancer: what do we know? Arch. Gynecol. Obstet. 2020;301(1):1–10. DOI: 10.1007/s00404-019-05358-8

26. Pejovic T., Thisted S., White M., Nezhat F.R. Endometriosis and endometriosis-associated ovarian cancer (EAOC). Adv. Exp. Med. Biol. 2020;1242:73–87. DOI: 10.1007/978-3-030-38474-6_5

27. Khan K.N., Fujishita A., Koshiba A., Kuroboshi H. et al. Biological differences between intrinsic and extrinsic adenomyosis with coexisting deep infiltrating endometriosis. Reprod. Biomed. Online. 2019;39(2):343–53. DOI: 10.1016/j.rbmo.2019.03.210

28. Chapron C., Vannuccini S., Santulli P., Abrão M.S. et al. Diagnosing adenomyosis: an integrated clinical and imaging approach. Hum. Reprod. Update. 2020;26(3):392–411. DOI: 10.1093/humupd/dmz049

29. Tellum T., Nygaard S., Lieng M. Noninvasive diagnosis of adenomyosis : a structured review and meta-analysis of diagnostic accuracy in imaging. J. Minim. Invasive Gynecol. 2020;27(2):408–18.e3. DOI: 10.1016/j.jmig.2019.11.001

30. Saraswat L., Ayansina D., Cooper K.G., Bhattacharya S. et al. Impact of endometriosis on risk of further gynaecological surgery and cancer: a national cohort study. BJOG. 2018;125(1):64–72. DOI: 10.1111/1471-0528.14793

31. Edi R., Cheng T. Endometriosis: evaluation and treatment. Am. Fam. Physician. 2022;106(4):397–404.

32. Vercellini P., Buggio L., Frattaruolo M.P., Borghi A. et al. Medical treatment of endometriosis-related pain. Best Pract. Res. Clin. Obstet. Gynaecol. 2018;51:68–91. DOI: 10.1016/j.bpobgyn.2018.01.015

33. Piacenti I., Viscardi M.F., Masciullo L., Sangiuliano C. et al. Dienogest versus continuous oral levonorgestrel/EE in patients with endometriosis: what's the best choice? Gynecol. Endocrinol. 2021;37(5):471–5. DOI: 10.1080/09513590.2021.1892632

34. Casper R.F. Progestin-only pills may be a better first-line treatment for endometriosis than combined estrogen-progestin contraceptive pills. Fertil. Steril. 2017;107(3):533–6. DOI: 10.1016/j.fertnstert.2017.01.003

35. Murji A., Biberoğlu K., Leng J., Mueller M.D. et al. Use of dienogest in endometriosis : a narrative literature review and expert commentary. Curr. Med. Res. Opin. 2020;36(5):895–907. DOI: 10.1080/03007995.2020.1744120

36. Hughes G.C., Choubey D. Modulation of autoimmune rheumatic diseases by oestrogen and progesterone. Nat. Rev. Rheumatol. 2014;10(12):740–51. DOI: 10.1038/nrrheum.2014.144

37. Collins M.K., McCutcheon C.R., Petroff M.G. Impact of estrogen and progesterone on immune cells and host-pathogen interactions in the lower female reproductive tract. J. Immunol. 2022;209(8):1437–49. DOI: 10.4049/jimmunol.2200454

38. Moulton V.R. Sex hormones in acquired immunity and autoimmune disease. Front. Immunol. 2018;9:2279. DOI: 10.3389/fimmu.2018.02279

39. Liu Y., Wang J., Zhang X. An update on the multifaceted role of NF-kappa B in endometriosis. Int. J. Biol. Sci. 2022;18(11):4400–13. DOI: 10.7150/ijbs.72707

40. Mita S., Shimizu Y., Notsu T., Imada K. et al. Dienogest inhibits Toll-like receptor 4 expression induced by costimulation of lipopolysaccharide and high-mobility group box 1 in endometrial epithelial cells. Fertil. Steril. 2011;96(6):1485–9.e4. DOI: 10.1016/j.fertnstert.2011.09.040

41. Arosh J.A., Sivakumar K.K., Lee J., Banu S.K. Effects of selective inhibition of prostaglandin E2 receptors EP2 and EP4 on the miRNA profile in endometriosis. Mol. Cell Endocrinol. 2022;558:111728. DOI: 10.1016/j.mce.2022.111728

42. Koshiba A., Mori T., Okimura H., Akiyama K. et al. Dienogest therapy during the early stages of recurrence of endometrioma might be an alternative therapeutic option to avoid repeat surgeries. J. Obstet. Gynaecol. Res. 2018;44(10):1970–6. DOI: 10.1111/jog.13725

43. Lee J.H., Song J.Y., Yi K.W., Lee S.R. et al. Effectiveness of dienogest for treatment of recurrent endometriosis: multicenter data. Reprod. Sci. 2018;25(10):1515–22. DOI: 10.1177/1933719118779733

44. Vignali M., Belloni G.M., Pietropaolo G., Barbasetti Di Prun A. et al. Effect of dienogest therapy on the size of the endometrioma. Gynecol. Endocrinol. 2020;36(8):723–7. DOI: 10.1080/09513590.2020.1725965

45. Del Pup L., Berretta M. As dienogest effectively suppress could it also reduce endometriosis associated ovarian cancers? A further motivation for long-term medical treatment. World Cancer Res. J. 2015;2(2):e526.

46. Vannuccini S., Luisi S., Tosti C., Sorbi F. et al. Role of medical therapy in the management of uterine adenomyosis. Fertil. Steril. 2018;109(3):398–405. DOI: 10.1016/j.fertnstert.2018.01.013

47. Ota I., Taniguchi F., Ota Y., Nagata H. et al. A controlled clinical trial comparing potentprogestins, LNG-IUS and dienogest, for the treatment of women with adenomyosis. Reprod. Med. Biol. 2021;20(4):427–34. DOI: 10.1002/rmb2.12408

48. Yang S., Liu Y., Wen J., Sun Y. et al. Clinical efficacy of dienogest versus levonorgestrel-releasing intrauterine system for adenomyosis. Evid. Based Complement Alternat. Med. 2022;2022:1995472. DOI: 10.1155/2022/1995472

49. Green I.C., Burnett T., Famuyide A. Persistent pelvic pain in patients with endometriosis. Clin. Obstet. Gynecol. 2022;65(4):775–85. DOI: 10.1097/GRF.0000000000000712